Challenges identifying efficacious miRNA therapeutics for cancer

References

• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469.
   PubMed Web of Science ®Google Scholar
• Li Y, Kowdley KV. MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics. 2012;10(5):246–253.
   PubMedGoogle Scholar
• Gilles M-E, Hao L, Huang L, et al. Personalized RNA-medicine for pancreatic cancer. Clin Cancer Res. 2018;24(7):1734–1747.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Kelnar K, Stahlhut C, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2015;34(27):3547–3555.
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12.
   PubMed Web of Science ®Google Scholar
• Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35(2):180–188.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qin Y-W, Brewer G. et al. MicroRNA degradation and turnover: regulating the regulators. Wiley Interdiscip Rev RNA. 2012;3(4):593–600.
   PubMed Web of Science ®Google Scholar
• Stepanov G, Zhuravlev E, Shender V, et al. Nucleotide modifications decrease innate immune response induced by synthetic analogs of snRNAs and snoRNAs. Genes (Basel). 2018;9(11):531.
   Web of Science ®Google Scholar
• Zhao C, Sun X, Li L. Biogenesis and function of extracellular miRNAs. ExRNA. 2019;1(1):38.
   Google Scholar
• Paliwal SR, Paliwal R, Vyas SP. A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery. Drug Deliv. 2015;22(3):231–242.
   PubMed Web of Science ®Google Scholar
• Denzler R, McGeary SE, Title AC, et al. Impact of MicroRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression. Mol Cell. 2016;64(3):565–579.
   PubMed Web of Science ®Google Scholar
• Meng Z, Lu M. RNA interference-induced innate immunity, off-target effect, or immune adjuvant? Front Immunol. 2017;8:331.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gao D-Y, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128–141.
   PubMed Web of Science ®Google Scholar
• Segal M, Biscans A, Gilles M-E, et al. Hydrophobically modified let-7b miRNA enhances biodistribution to NSCLC and downregulates HMGA2 in vivo. Mol Ther Nucleic Acids. 2020;19:267–277.
   PubMedGoogle Scholar
• Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 2011;18(12):1111–1120.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Javanzad S, Saleh T, et al. Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother. 2014;10(2):321–332.
   PubMed Web of Science ®Google Scholar
• Gasparello J, Manicardi A, Casnati A, et al. Efficient cell penetration and delivery of peptide nucleic acids by an argininocalix[4]arene. Sci Rep. 2019;9(1):3036.
   PubMed Web of Science ®Google Scholar
• Karlsen TA, Brinchmann JE. Liposome delivery of MicroRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I. Mol Ther. 2013;21(6):1169–1181.
   PubMed Web of Science ®Google Scholar
• Li J, Liang H, Liu J, et al. Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy. Int J Pharm. 2018;546(1):215–225.
   PubMed Web of Science ®Google Scholar
• Biscans A, Coles A, Haraszti R, et al. Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo. Nucleic Acids Res. 2018;47(3):1082–1096.
   Web of Science ®Google Scholar
• Daei P, Ramezanpour M, Khanaki K, et al. Aptamer-based targeted delivery of miRNA let-7d to gastric cancer cells as a novel anti-tumor therapeutic agent. Iran J Pharm Res. 2018;17(4):1537–1549.
   PubMed Web of Science ®Google Scholar
• Li X, Corbett AL, Taatizadeh E, et al. Challenges and opportunities in exosome research-perspectives from biology, engineering, and cancer therapy. APL Bioeng. 2019;3(1):011503.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Viral vectors in gene therapy. Diseases. 2018 May 21;6:2.
   Google Scholar
• Salah Z, Abd El Azeem EM, Youssef HF. et al. Effect of tumor suppressor MiR-34a loaded on ZSM-5 nanozeolite in hepatocellular carcinoma: in vitro and in vivo approach. Curr Gene Ther. 2019;19(5):342–354.
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages [Review Article]. Res Pharm Sci. 2018 July 1;13(4):288–303.
   PubMed Web of Science ®Google Scholar
• Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell. 2019;179(5):1033–1055.
   PubMed Web of Science ®Google Scholar
• Christie RJ, Nishiyama N, Kataoka K. Minireview:delivering the code: polyplex carriers for deoxyribonucleic acid and ribonucleic acid interference therapies. Endocrinology. 2010;151(2):466–473.
   PubMed Web of Science ®Google Scholar
• Linsley CS, Wu BM. Recent advances in light-responsive on-demand drug-delivery systems. Ther Deliv. 2017;8(2):89–107.
   PubMed Web of Science ®Google Scholar
• Bilensoy E. Cationic nanoparticles for cancer therapy. Expert Opin Drug Deliv. 2010;7(7):795–809.
   PubMed Web of Science ®Google Scholar
• Biscans A, Coles A, Haraszti R, et al. Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo. bioRxiv. 2018;47(3):1082–1096.
   Google Scholar
• Esposito CL, Cerchia L, Catuogno S, et al. Multifunctional Aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther. 2014;22(6):1151–1163.
   PubMed Web of Science ®Google Scholar
• Suter SR, Ball-Jones A, Mumbleau MM, et al. Controlling miRNA-like off-target effects of an siRNA with nucleobase modifications. Org Biomol Chem. 2017;15(47):10029–10036.
   PubMed Web of Science ®Google Scholar
• Lai X, Eberhardt M, Schmitz U, et al. Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer. Nucleic Acids Res. 2019;47(15):7753–7766.
   PubMed Web of Science ®Google Scholar
• Bandi N, Vassella E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011;10(1):55.
   PubMed Web of Science ®Google Scholar
• Yu H-R, Huang L-H, Li S-C. Roles of microRNA in the immature immune system of neonates. Cancer Lett. 2018;433:99–106.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hardie J, Zhang X, et al. Effects of engineered nanoparticles on the innate immune system. Semin Immunol. 2017;34:25–32.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222.
   PubMed Web of Science ®Google Scholar
• Foss FM, Querfeld C, Kim YH, et al. Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL. J clin oncol. 2018;36(15_suppl):2511.
   Web of Science ®Google Scholar
• Teplyuk NM, Uhlmann EJ, Gabriely G, et al. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic. EMBO Mol Med. 2016;8(3):268–287.
   PubMed Web of Science ®Google Scholar